Recombinant Human BCA-1 (CXCL13)
Catalog No : IGX-RP458
3508.60€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
Product name | Recombinant Human BCA-1 (CXCL13) | ||
---|---|---|---|
Catalog No | IGX-RP458 | ||
Supplier’s Catalog No | IGX-RP458 | ||
Supplier | ImuGeX | ||
Source antigen | E. coli | ||
Reactivity | Human | ||
Cross reactivity | |||
Applications | |||
Molecular weight | 10 |
Storage | -70°C | ||
---|---|---|---|
Other names | BLC, B cell Attracting Chemokine-1, CXCL13, C-X-C motif chemokine 13, BCA1 | ||
Grade | Highly Purified | ||
Purity | >95% as determined by SDS-PAGE | ||
Form | Recombinant BCA-1 was lyophilized from a 0.2 μm filtered 20 mM PB,100 mM NaCl solution pH 7.5. | ||
Reactivity life | 6 months | ||
Note | For reserch purpose only | ||
Purity | >95% as determined by SDS-PAGE | ||
Description | The homeostatic chemokine CXCL13 is constitutively expressed in secondary lymphoid tissue and initiates lymphoid neogenesis when expressed aberrantly in mice. CXCL13 has also been detected in chronic inflammation associated with human lymphoid neogenesis, suggesting a pathogenic role. Follicular dendritic cells (FDCs) are generally considered to be the major source of CXCL13 both in normal and aberrant lymphoid tissue. CXCL13 has been the exclusive ligand for CXCR5, which initiates chemotaxis toward an increasing gradient in vitro and to B cell zones in lymph nodes that express CXCL13. More recently, CXCR5 expression has also been shown in DN T cells in mice, a subset of CD4 follicular Th cells, and some tonsillar CD4+ and CD25+ Tregs in humans. |
© 2020 Imugex All Rights Reserved